NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
about
Editorial: Dementia, Frailty and Aging.Phenotypic Heterogeneity in Dementia: A Challenge for Epidemiology and Biomarker Studies.Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosureAmyloid-associated increases in longitudinal report of subjective cognitive complaintsDisclosure of amyloid positron emission tomography results to individuals without dementia: a systematic reviewDiagnosis of neurodegenerative dementia: where do we stand, now?Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's diseaseBlood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanismAberrant functional connectivity network in subjective memory complaint individuals relates to pathological biomarkersDiagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE projectPopulation Health Solutions for Assessing Cognitive Impairment in Geriatric PatientsAtrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkersSystematic Review on Resting-State EEG for Alzheimer's Disease Diagnosis and Progression AssessmentDisrupted Functional Connectivity of Cornu Ammonis Subregions in Amnestic Mild Cognitive Impairment: A Longitudinal Resting-State fMRI StudyCSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer diseaseHow early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lectureNon-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's diseaseAssociation between white matter lesions and cerebral Aβ burdenDetection of Alzheimer's DiseaseThe genetic risk of Alzheimer's disease beyond APOE ε4: systematic review of Alzheimer's genetic risk scoresAutomation vs. Experience: Measuring Alzheimer's Beta-Amyloid 1-42 Peptide in the CSFF-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's diseaseBrainstem Imaging in Alzheimer's Disease: Potential for Biomarker DevelopmentDecreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer's DiseaseProteomic Approaches for the Discovery of Biofluid Biomarkers of Neurodegenerative DementiasDistinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive DeclineStudy partners: essential collaborators in discovering treatments for Alzheimer's diseaseTen Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
P2860
Q55266498-5401F301-6E52-4BEB-A9B6-7D6FEB6D2709Q55512073-2B9577A7-25C1-4E97-BADB-69C795BB5141Q56373543-6D78C2FB-F8FF-47FB-A26E-DD460FD1D18BQ57159910-82C9B6FE-A84C-4DE4-BDE1-1942FA2AFE7CQ57174282-8931D64D-FF71-45DB-855B-92A2A4575672Q57300558-D3230B89-DCD6-4F2B-9EE9-20A35F043D55Q57800439-173DB61D-CAB2-406F-A8B0-D59A360CF4D7Q57810850-78991D04-AFC0-42DB-A615-AF89582227A7Q58121166-44078CAE-01EC-4D20-AF9E-9A779947C7D5Q58554957-B794CBC1-EAF7-4A2D-A6E6-3A2CC1D09960Q58556716-415AD27F-1E39-4D58-920D-13963C386A5FQ58577311-A8E0CFAB-37AB-4239-8326-D6F0927442D0Q58583583-DE9C43CA-85F4-4779-8EFC-07D1E6A9BCC1Q58694818-30567E03-5895-414D-B37B-40036B133725Q58697672-6917497D-96D5-4EDD-9038-BA5C4CB2EE4CQ58697674-4DDBB0B1-2D07-489B-B3C4-0A4B17320A91Q58698516-E014866A-9EC9-450E-8559-D5FEC067956AQ58701393-0C23A6C9-8EE8-454D-9B73-BE1745F8C92EQ58706105-CF030DBC-259A-44CB-940E-F1B94EFE5840Q58707802-CE987B42-4505-45BA-884C-315C54AB7F5CQ58719736-193A0378-A262-4A21-A63C-FB0706E7D565Q58733228-679EE388-EE74-40A5-A59C-517F25C57789Q58750830-CF1A2676-5858-43CB-B594-4054BD3E7EBDQ58758801-A9366DD1-EB14-4AD6-8590-5BBF440A98B9Q58779295-2FB9159C-4DA8-43A8-BCF8-7C1F466D5339Q58797397-1C5BC757-BB26-4A9D-9971-1BE4CA710373Q59128442-CD6A9DBF-3ED9-4DBF-A478-1058B2CB8593Q59137449-56352990-498A-450A-81A3-99746CD045D6
P2860
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
@en
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
@nl
type
label
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
@en
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
@nl
prefLabel
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
@en
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
@nl
P2093
P2860
P50
P1476
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
@en
P2093
Billy Dunn
Christopher C Rowe
Contributors
Creighton Phelps
David A Bennett
Eric Siemers
Frank Jessen
Heather M Snyder
Jose Luis Molinuevo
P2860
P304
P356
10.1016/J.JALZ.2018.02.018
P50
P577
2018-04-01T00:00:00Z